Paying For Silence: Evaluating Reverse Payment Settlements Under Modern Antitrust Frameworks
Harsh Chawla, National Law Institute University, Bhopal
Vardhman Jothe, National Law Institute University, Bhopal
ABSTRACT
A reverse payment settlement resolves patent litigation between an originator pharmaceutical company and a generic challenger in an inversion of the ordinary logic of settlement: the patentee, not the alleged infringer, pays, and in return the generic agrees to stay out of the market until a date it might otherwise have entered earlier. The practice has produced three distinct regulatory answers, each considered in turn in this article. Part II sets out the economic logic underlying such settlements, explaining why a payment exceeding the payor's own anticipated litigation costs, unexplained by any independently verifiable service, functions as a reliable signal of an anticompetitive purpose rather than a genuine litigation compromise. Part III surveys the doctrinal path taken by three jurisdictions: the Supreme Court of the United States, in FTC v Actavis, subjected such settlements to the ordinary antitrust rule of reason, an indeterminate standard that a decade of subsequent litigation has struggled to operationalise; the Court of Justice of the European Union, in Lundbeck and, more decisively, in the Servier judgments, has instead treated sufficiently large and unexplained value transfers as restrictions of competition by object, trading doctrinal certainty for a risk of over-inclusiveness; and India has adopted neither position, since no reported order has ever resolved whether Section 3 of the Competition Act, 2002, read with the intellectual property exemption in Section 3(5), even reaches such settlements at all. Part IV evaluates the comparative costs of each framework, and Part V proposes a structured presumption, anchored to payment size rather than patent validity, that the Competition Commission of India could adopt within its existing statutory text. The article concludes that India, as the jurisdiction with the world's largest generic pharmaceutical industry, can no longer afford the doctrinal silence its competition authority has maintained for over a decade.
